NCT07921966
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Pharmacokinetic parameters of olanzapine in plasma
Timeframe: Time zero to 14 days postdose
Arms and interventions
NRL 1004 25 mg/mL solutionExperimental
NRL-1004 (olanzapine nasal spray), 25 mg/mL solution
NRL-1004 50 mg/mL solutionExperimental
NRL-1004 (olanzapine nasal spray), 50 mg/mL solution
NRL-1004 75 mg/mL solutionExperimental
NRL-1004 (olanzapine nasal spray), 75 mg/mL solution
NRL-1004 100 mg/mL solutionExperimental
NRL-1004 (olanzapine nasal spray), 100 mg/mL solution
ZYPREXA IM 10mg/vialActive comparator
ZYPREXA IntraMuscular (olanzapine) Injection, Powder, for Solution for Intramuscular use, 10 mg/vial
Drugs: NRL-1004 2.5 mg, ZYPREXA IM 10mg, NRL-1004 5.0 mg, NRL-1004 7.5 mg, NRL-1004 10.0 mg